Member Info for Fadec92

Utah and Blue my view is Sareum have only just got to the stage where a deal is possible with the candidates selection last year and they have only recently sought a Formulation for Manufacturing to Produce SDC-1801!

Plus the recent activities have focused on toxicology studies designed to gain insight to the maximum-tolerated doses (MTD) you would think that a major need this information!

“Multiple dose-finding studies are now ongoing to identify doses to use in specific toxicology studies, which are intended to form part of the applications for initial human trials. Additional research to refine the clinical plans, including prioritisation of potential target indications, is continuing”

It’s a case of when it’s time!

Now you would think that a closer look by anyone interested would be :-

“Data arising from some of this work are being prepared for submission to a peer-reviewed publication and a conference presentation.”

Sareum are Looking to license between now or after pre-clinical safety study’s through to in the clinic!

With Celgene option with Nimbus it was taking up with the release of clinical trial data!

I suspect they were further advanced with the biotechs having the data!

Its good enough already according to Sareum CEO Tim and if it wasn’t good enough with the statements below they would be designing Clinical Trials!

Convinced - “gaining increasing clinical validation and we are convinced”

"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas.”

Efficacy - “compelling efficacy seen in disease models”

“Both Sareum programmes have progressed well since candidate nomination in September 2018, building on the compelling efficacy seen in disease models, the potential for once-daily oral dosing and good early safety profiles. Data arising from some of this work are being prepared for submission to a peer-reviewed publication and a conference presentation”

Toxicology - “currently demonstrating excellent tolerability“

“Sareum's recent activities have focused on toxicology studies designed to gain insight to the maximum-tolerated doses (MTD) of SDC-1801 and SDC-1802 in rodents. SDC-1801 is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; an MTD has yet to be reached.“

Positive Statements - “clear opportunity to generate significant value for our shareholders“

For anyone new that hasn’t read the trial of SDC-1801 for Lupus at SRI International, Menlo Park, CA.

What was the impact on the development of the principal discipline(s) of the project?

“We have preliminary evidence of reducing pathogenic auto-antibodies in mouse model of lupus without effecting the normal balance of the immune cell subsets. This approach is novel and may lead to development of a therapy for lupus which doesn’t involve systemic immuno-suppression with harmful side effects.”

What was the impact on society beyond science and technology?

“This approach may open up additional treatment approaches for lupus. The standard of care is little changed in 50 years, so there is a need for new treatment options. Lupus particularly targets women in their most productive years (child bearing age) of life. Our current approach may benefit numerous lupus patients and improve their quality of life and productive contribution to society.”

https://apps.dtic.mil/dtic/tr/fulltext/u2/1048482.pdf

There’s always mention of Autoimmune Diseases, but not in Cancer as SDC-1802 is formally selected with development as a potential new targeted therapy for certain cancers.

Overlooked in my view no excitement around this on here and a second thought but on the other hand it could be a blockbuster on its own, guess we will see with the peer publication and conference data, must be a lot more insight with clinical study’s being developed!

For Autoimmune a look back in sept 2018 by Robin Davidson love looking at his reviews, he always puts Sareum into the picture when the big guns are singing their own praises on Twitter!

“If the BMS-98615 psoriasis data are strong, some investors may also be interested in the potential read-across to a little-known UK microcap Sareum (SAR), which is one of only three other companies known to have a TYK2 inhibitor in formal development. The other two are Pfizer, which has a TYK2/JAk1 inhibitor, PF-06700841 that is in mid stage studies for psoriasis, Crohn’s disease and ulcerative colitis (UC), and the private US company, Nimbus Therapeutics. Both Sareum and Nimbus are in late preclinical development“

https://quoteddata.com/2018/09/bms-to-disclose-tyk2-inhibitor-data-that-backed-phase-iii-move-for-psoriasis/

Stoney sometimes it’s easy to overlook what Sareum has to offer, with Chk1 taking center stage as a validation off the model and a benchmark, I haven’t come across any research of a company offering a Tyk2 for Cancer, has anyone?

5:50 onwards!

https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html

“It’s a matter of keeping the interested party’s informed”

Noodle there is certainly is a couple of Full Spectrum Products on this site!

This will be interesting too suitors!

“Data arising from some of this work are being prepared for submission to a peer-reviewed publication and a conference presentation.”

Potnak here is Tim saying in Interview Discussion are going on for Tyk2 SDC-1801 and SDC-1802.

“Keeping the interested party’s informed and when they have sufficient data for their needs then look what a licensing deal can look like”

And

“To Look to license between now or certainly after pre-clinical safety study’s through to in the clinic”

https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html

Looked at the products from 101 and these are full spectrum oils and not premium CBD isolated as Joy mentioned!

The base is MCT oil (medium chain triglyceride). The unflavoured product has a slight taste of coconut oil - which is full of MCTs. MCTs are of dietary interest also.

So Zoetic products are a long way from the brown, smelling whole plant oils normally seen in the UK or from as JJAL highlights from 101 cbd oils!

Good assessment BH and acknowledgement that it hasn’t been exactly plain sailing as we all know the extra wells in the lower sections hasn’t progressed as we thought that a deal would come at some point between True and Renegade for an extra 16 wells, I think it was aimed for to progress the wells this year I’m sure was said after the completion of the 15-16 pad after assessment of flows declines but with the total focus on Zoetic I’m unsure if this will happen as Nick Tullock said in the interview but he did say at the end that we an oil and gas company with upside from the other projects so maybe now there might be time to move the other projects forward but I suppose that is dependent on cash flow from the Hemp/CBD element to do this!

I’ll be very happy to hear that the oil and gas aspect has been worked on with discussions with True or other Operators in area that they have had good working relationships with, so for me this is important and will sort of vindicate RP as that he can progress the projects we have still and move them forward but it is then totally reasonable to think that if a big revenues can be made from Zoetic then it’s sensible to progress this first!

So I look forward to add these Zoetic revenues to add to East Denver revenues to build up the company in DT/ED and bigger Hemp business in U.K. AND US but would like more feedback from the RP that this is the plan as I’m sure then the balanced negatives can be expelled as we know we do have a plan for other projects I would be much happier!

https://www.linkedin.com/feed/update/urn:li:activity:6551741222376087552

https://www.thetimes.co.uk/article/costain-s-stock-is-rolling-again-after-upgrades-bv5nd7958

https://imgur.com/a/rA0VqkQ

https://imgur.com/a/uKVItvr

Halliburton’s Managed Flowback, 1.20!

https://m.youtube.com/watch?v=m6OHFTEdRGw

There is no problem with the wells, all wells in area after time need artificial lift, ie the rod pump lift system is most common in area and have some photos while in Denver of key ConocoPhillips wells with rod pumps, also since the regulatory changes in Colorado there has been less permitting because the cogcc needed time to implement new oil and gas operating guidance and both sides still deciding with discussion around the laws of environment and cutting red tape, some poor trolling going on here again!

It’s very apparent that the trolls dosn’t know what’s involved operationally with ED!

“During June, two of the new wells were taken offline for workovers, during which time a gas lift was applied to assist production. The operations were completed successfully and both wells are now back on production.”

That’s a good find Thoth and another versatile potential combination which synergies with a different Cancer Drug!

“Currently, ongoing work is focused on the in vivo testing of gemcitabine in combination with CHK1 and WEE1 inhibitors as a novel therapeutic approach for the treatment of Ewing sarcoma.”

Got too be room here for a big company to be interested with the only Chk1 inhibitor that has been shown to work with excellent results ie SRA737 being trialed in combination with Keytruda completely regressed SCLC tumours in mouse models and also the PARP inhibitor combination with Niraparib trial design, these cancer drugs are the reason for the recent success in big biopharma’s and will continue to look for new additions to continue to outperform the sector!

“The powerhouse that is Keytruda helped to keep Merck & Co in the top flight, while Astrazenca’s wins in lung cancer with Imfinzi and promise in pancreatic cancer for Lynparza have lifted the shares since the beginning of the year.”

Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.

https://www.evaluate.com/node/14839/amp?__twitter_impression=true

They take a biopsy of the patients tumor to select an immunotherapy, next generation immuno-oncology thinking out loud some cancers evade detection like the example of Mercks Keytruda in SCLC with SRA737 as a key element with MD Anderson research that highlights to the immune system where the cancer is to attack, with Gritstone Technology it’s Tailored to specific tumor type of patient based on their proprietary prediction software, maybe they need a synthetic molecule like SRA737 to target cancer cells for their immuno-oncology therapy to seek and necrosis (cell death), being broad based and the only DDR Chk1 molecule you could probably see a lot of companies wanting combination therapies to cure Cancer!

Peer review is the evaluation of work by one or more people with similar competences as the producers of the work (peers). It functions as a form of self-regulation by qualified members of a profession within the relevant field. Peer review methods are used to maintain quality standards, improve performance, and provide credibility. In academia, scholarly peer review is often used to determine an academic paper's suitability for publication.